Australia is anticipating the introduction of Retatrutide, a novel medication by Novo Nordisk. This dual-action drug, targeting both GLP-1 and GIP receptors, has shown impressive performance in research studies, https://faymduq444659.buscawiki.com/2603791/novo_nordisk_s_retatrutide_australia_a_potential_advancement_for_weight_management